How can Biotech startups best manage to survive the “Valley of Death”? Our experts from WIPITS Life Sciences practice group Benedikt Mahr, Britta Neß and Kai Grunwald, have analysed some of the key legal factors that help companies transition their academic innovation into clinical studies and a successful business. To find out more about these key factors for survival, take a look at their article in the special issue on “Life Sciences” of the Venture Capital Magazin, available at https://lnkd.in/dmQiXs2c